The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 521-526

  Hamilton, Chad A ^a   Miller, Austin ^b   Miller, Caela ^a   Krivak, Thomas C ^c   Farley, John H ^a   Chernofsky, Mildred R ^d   Stany, Michael P ^a   Rose, G Scott ^a   Markman, Maurie ^e   Ozols, Robert F ^f   Armstrong, Deborah K ^g   Maxwell, G Larry ^a,h  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Sibley Memorial Hospital   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Cytoreduction; Epithelial ovarian cancer; Microscopic residual

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ABDOMINAL DISEASE; ABDOMINAL PERITONEAL DISEASE; ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE SEVERITY; EPITHELIAL OVARIAN CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MICROSCOPY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PELVIS TUMOR; PERITONEAL DISEASE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL CANCER; REVIEW; UPPER ABDOMINAL DISEASE;

EID: 80051552533     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.041     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J Clin, 2010.
2. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259 (Pubitemid 34177431)
3. A.N. Fader, and P.G. Rose Role of surgery in ovarian carcinoma J Clin Oncol 25 2007 2873 2883 (Pubitemid 47123151)
4. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 42 1975 101 104
5. S.M. Eisenkop, N.M. Spirtos, and W.C. Lin "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary Gynecol Oncol 103 2006 329 335 (Pubitemid 44389875)
6. G.A. Omura Progress in gynecologic cancer research: the Gynecologic Oncology Group experience Semin Oncol 35 2008 507 521
7. W.E. Winter 3rd, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627 (Pubitemid 47372600)
8. G.D. Aletti, S.C. Dowdy, B.S. Gostout, M.B. Jones, C.R. Stanhope, and T.O. Wilson Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Obstet Gynecol 107 2006 77 85
9. S.M. Eisenkop, N.M. Spirtos, R.L. Friedman, W.C. Lin, A.L. Pisani, and S. Perticucci Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study Gynecol Oncol 90 2003 390 396 (Pubitemid 36952033)
10. D.S. Chi, E.L. Eisenhauer, J. Lang, J. Huh, L. Haddad, and N.R. Abu-Rustum What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103 2006 559 564 (Pubitemid 44602167)
11. S. Kommoss, J. Rochon, P. Harter, F. Heitz, J.P. Grabowski, and N. Ewald-Riegler Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer Ann Surg Oncol 17 2010 279 286
12. P. Harter, F. Hilpert, S. Mahner, S. Kommoss, F. Heitz, and J. Pfisterer Prognostic factors for complete debulking in first- and second-line ovarian cancer Int J Gynecol Cancer 19 Suppl 2 2009 S14 S17
13. S.C. Crawford, P.A. Vasey, J. Paul, A. Hay, J.A. Davis, and S.B. Kaye Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial J Clin Oncol 23 2005 8802 8811 (Pubitemid 46211526)
14. W.J. Hoskins, B.N. Bundy, J.T. Thigpen, and G.A. Omura The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 1992 159 166 (Pubitemid 23001322)
15. D.S. Chi, and P.E. Schwartz Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer Gynecol Oncol 111 2008 391 399
16. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
17. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clarke-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 2001 1001 1007 (Pubitemid 32176274)
18. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
19. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
20. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
21. D.R. Cox Regression models and life tables (with discussion) J R Stat Soc Series B 34 1972 187 220
22. G.D. Aletti, and W.A. Cliby Importance of surgical aggressiveness in advanced ovarian cancer J Clin Oncol 24 2006 2397 author reply 2398-9 (Pubitemid 46630681)
23. D.S. Chi, and R.R. Barakat Aggressive surgery and ovarian cancer J Clin Oncol 24 2006 2395 2396 author reply 2396-7
24. S.C. Crawford, J. Paul, and S.B. Kaye Aggressive surgery and ovarian cancer; authors reply J Clin Oncol 24 2006 2396 2397
25. D.S. Chi, E.L. Eisenhauer, O. Zivanovic, Y. Sonoda, N.R. Abu-Rustum, and D.A. Levine Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm Gynecol Oncol 114 2009 26 31
26. O. Zivanovic, E.L. Eisenhauer, Q. Zhou, A. Iasonos, P. Sabbatini, and Y. Sonoda The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer Gynecol Oncol 108 2008 287 292 (Pubitemid 351174284)
27. W.E. Winter 3rd, G.L. Maxwell, C. Tian, M.J. Sundborg, G.S. Rose, and P.G. Rose Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 26 2008 83 89
28. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
29. E.L. Eisenhauer, N.R. Abu-Rustum, Y. Sonoda, D.A. Levine, E.A. Poynor, and C. Aghajanian The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer Gynecol Oncol 103 2006 1083 1090 (Pubitemid 44821338)
30. O. Zivanovic, C.S. Sima, A. Iasonos, W.J. Hoskins, P.R. Pingle, and M.M. Leitao Jr. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum Gynecol Oncol 116 2010 351 357
31. A. Berchuck, E.S. Iversen, J.M. Lancaster, H.K. Dressman, M. West, and J.R. Nevins Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays Am J Obstet Gynecol 190 2004 910 925 (Pubitemid 38561506)
32. A.L. Covens A critique of surgical cytoreduction in advanced ovarian cancer Gynecol Oncol 78 2000 269 274
33. M. Markman Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action J Clin Oncol 25 2007 4168 4170 (Pubitemid 47548554)
34. J.Y. Hou, M.G. Kelly, H. Yu, J.N. McAlpine, M. Azodi, and T.J. Rutherford Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 2007 211 217 (Pubitemid 46441463)
35. K.K. Zorn, C. Tian, W.P. McGuire, W.J. Hoskins, M. Markman, and F.M. Muggia The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study Cancer 115 2009 1028 1035